Chosa Oncology

0.86 SEK

-6.52 %

Less than 1K followers

CHOSA

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

-6.52 %

-30.65 %

-53.01 %

+13.98 %

+9.49 %

+15.26 %

-46.59 %

-95.82 %

-93.18 %

Chosa Oncology is a Swedish-Danish biotechnology company that develops solutions for personalized cancer treatment with a focus on diagnostics and drug formulation. The company targets healthcare providers and research actors and works internationally with partners and clinical projects. Chosa Oncology was founded in 2022 and is headquartered in Lund, Sweden.

Market cap

67.85M SEK

Turnover

39K SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

26.2

2026

Annual report '25

27.5

2026

General meeting '26

All

Press releases

ShowingAll content types

Press release11/10/2025, 9:00 AM

Chosa Oncology AB: CHOSA - Platinum chemotherapy is the backbone of PD-1/PD-L1-based lung cancer therapy

Press release10/20/2025, 10:00 AM

Chosa Oncology AB: CHOSA's presented data on the carboplatin response predictor in breast cancer patients on the ESMO conference

Press release10/7/2025, 1:28 PM

Chosa Oncology AB: CHOSA Wins 2025 Jiangning International Entrepreneurship Contest (Greater Shanghai region), China

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release9/30/2025, 11:03 AM

Chosa Oncology AB: CHOSA announces positive results from a clinical study in collaboration with ETOP/EORTC on platinum predictor in lung cancer

Press release8/8/2025, 6:00 AM

Chosa Oncology AB: CHOSA's presents data on the carboplatin response predictor in breast cancer patients on the annual ESMO conference

Regulatory press release8/1/2025, 12:29 PM

Chosa Oncology AB: Chosa Oncology's warrants of series TO 2 to be admitted to trading

Regulatory press release7/31/2025, 3:25 PM

Chosa Oncology AB: Chosa Oncology announces the last day of trading in BTU

Regulatory press release7/1/2025, 2:19 PM

Chosa Oncology AB: CHOSA extends the timeline for biopsy collection prior to publication from the SPLENDOUR study

Regulatory press release6/27/2025, 1:48 PM

Chosa Oncology AB: Chosa Oncology announces outcome in rights issue

Regulatory press release6/25/2025, 10:00 AM

Chosa Oncology AB: Last subscription day in Chosa's subscription period

Regulatory press release6/25/2025, 7:15 AM

Chosa Oncology AB: CHOSA files new patent application to predict which patients may benefit from platinum chemotherapy and immunotherapy

Regulatory press release6/13/2025, 11:42 AM

Bulletin from the annual general meeting on 13 June 2025 in Chosa Oncology AB

Regulatory press release6/12/2025, 6:45 AM

The subscription period in Chosa Oncology AB's rights issue begins today - the company invites to a webcast presentation

Regulatory press release6/10/2025, 2:04 PM

Chosa Oncology AB publishes information document in connection with rights issue of units

Press release6/9/2025, 2:51 PM

Chosa Oncology AB: CHOSA Oncology invites investors to two upcoming presentations

Regulatory press release6/2/2025, 6:45 AM

Chosa Oncology AB resolves on a directed issue of units and on a rights issue of units to provide funds for reaching several value-enhancing milestones

Regulatory press release5/13/2025, 12:48 PM

Notice of annual general meeting in Chosa Oncology AB

Regulatory press release5/9/2025, 1:44 PM

Chosa Oncology AB: CHOSA- Extending CHOSA's Platin DRP: Predicting Carboplatin Efficacy in Breast Cancer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.